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BACKGROUND: The combination of propofol-remifentanil for procedural deep seda-
tion in spontaneously breathing patients is characterized by the frequent incidence
of side effects, especially respiratory depression. These side effects may be due to
either the drug combination or the drug delivery technique. Target-controlled
infusion (TCI) might optimize drug delivery. In this prospective, randomized,
double-blind study in patients undergoing elective colonoscopy, we thus tried to
answer two questions: first, if adding remifentanil to propofol surpasses the
disadvantages of the combination of these two products, and second, if adminis-
tration of remifentanil via TCI decreases the incidence of side effects, compared to
manually controlled administration.
METHODS: Patients undergoing elective colonoscopy were randomly assigned to
receive remifentanil via manually controlled continuous infusion (MCI) (0.125
g  kg1  min1 for 2 min followed by a continuous infusion of 0.05
g  kg1  min1), TCI remifentanil (1 ng/mL), or placebo (normal saline either as
TCI or manual infusion of equivalent rate). All patients received TCI propofol,
adjusted to a target concentration level that provided deep sedation in which
patients were not responsive to verbal commands, but maintained spontaneous
ventilation without assistance.
RESULTS: Significantly more patients in the placebo group showed movement,
cough and hiccup, which transiently interfered with the examination. There were
no clinically significant differences in hemodynamic or recovery variables among
all groups. Remifentanil administered via TCI resulted in a decrease in propofol
requirements. The incidence of hypopnea and apnea was less frequent when
remifentanil was administered via TCI compared to MCI (TCI n  7, MCI n  16,
P  0.05).
CONCLUSION: The combination of remifentanil and propofol for deep sedation in
spontaneously breathing patients, offered better conditions for colonoscopy than
propofol used as a single drug. Remifentanil administered via TCI resulted in a
decrease in propofol dosing and in a lower incidence in apnea and respiratory
depression (TCI n  7, MCI n  16, P  0.05), compared to manually controlled
administration of remifentanil.
(Anesth Analg 2009;108:828–34)
For deep sedation in spontaneously breathing pa-
tients, the combination of propofol and remifentanil is
increasing in popularity. However, the ability to pro-
vide adequate amnesia, immobility and analgesia is
limited by the ventilatory depression associated with
both propofol and remifentanil.1–4 The combination of
both products, even in low doses, results in a strik-
ingly synergistic respiratory depression.5 In previous
work, we compared manually controlled infusion
(MCI) of remifentanil versus placebo to supplement
MCI propofol during spontaneous respiration.1 We
concluded that, due to the enormous interindividual
variability in calculated effect-site concentrations, MCI
remifentanil in combination with MCI propofol is not
a reliable technique during spontaneous respiration.
The administration of drugs via target-controlled
infusion (TCI) allows achievement of a defined target
concentration without overshoot and overdosing,6
which is common when using manual infusions1 and
which is responsible for the respiratory side effects.7
TCI versus MCI of remifentanil used to supplement
propofol during spontaneous respiration has not been
compared. The aim of this study was twofold. First, to
examine if the addition of remifentanil to propofol TCI
would result in more beneficial conditions during
procedural deep sedation, and second, if there was a
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further benefit if remifentanil was administered via
TCI compared to manual administration. Therefore,
we evaluated the effect of these regimens with regards
to (a) calculated propofol and remifentanil plasma and
effect-site concentrations, (b) hemodynamic and re-
covery variables, and (c) adverse events, with a special
focus on respiratory side effects. We hypothesized that
remifentanil administration via TCI would exhibit
fewer respiratory effects, and thus contribute to a safer
and more reliable technique for coadministration of
propofol and remifentanil in spontaneously breathing
patients.
We want to emphasize that patients undergoing
colonoscopy were only chosen as a study population.
The reader must be cautioned that this article is not at
all meant to make any clinical recommendations con-
cerning deep sedation for colonoscopy.
METHODS
After local Ethics’ Committee (Ethics’ Committee,
Ghent University Hospital, Gent, Belgium) approval,
written informed consent was obtained from all pa-
tients. Sixty nonpremedicated outpatients, ASA physi-
cal status I or II, ages 18–65 yr, scheduled for a
complete colonoscopy were randomly included in the
study. Patients with a history of allergic reactions to
any of the study drugs or chronically receiving opioid
analgesics or sedative medication were excluded. All
patients received 45 mL Fleet phospho soda for bowel
preparation.
Patients received no preanesthetic medication. After
consent had been obtained, but before any anesthetic or
surgical interventions, successive envelopes containing
allocation to one of the three treatment groups were
opened by the deep sedation nurse when patients were
in the preoperative holding area. Two groups received
remifentanil, one group with MCI (MCI R group, n 
19), the other group with TCI (TCI R group, n 20). The
third group received placebo (normal saline, n 21). To
exclude bias and maintain blinding, patients received
normal saline either via MCI (n  11) or TCI (n  10).
Except for the nurse opening the envelope and prepar-
ing the syringes, everyone was blinded. This nurse did
not take part further in the study. Blinding was guaran-
teed by providing the remifentanil or normal saline in
coded syringes identified only with the treatment num-
ber and patient’s initials. Peripheral IV access was estab-
lished at the opposite arm of the noninvasive blood
pressure cuff and a 500 mL crystalloid infusion was
commenced. The solution of remifentanil (20 g/mL) or
placebo and propofol were connected directly to the IV
cannula using a three-way tap. In the groups receiving
TCI, the target plasma concentration of the study drug
(remifentanil or normal saline) was set at 1 ng/mL. In
the MCI group, the study drug infusion was started at a
rate of 0.125 g  kg1 min1 for 2 min (i.e., a bolus dose
of 0.25 g/kg given over 2 min), followed by a continu-
ous infusion of 0.05 g  kg1 min1. For calculation of
the infusion rate, total body weight was used. The
remifentanil infusions (in the MCI group) or the target
plasma concentrations (in the TCI group) were kept at
the same rate/concentration throughout the procedure.
Two minutes after the start of remifentanil/placebo,
propofol administration was started using plasma-
controlled TCI, at an initial target concentration of 4
g/mL in all 3 groups. When loss of consciousness
(LOC) was achieved, which was defined as unrespon-
siveness to both verbal and tactile stimuli, the target
plasma concentration of propofol (Cpprop) was set at
the same concentration as the calculated effect-site
concentration of propofol (Ceprop) at which LOC
occurred. When LOC was not achieved at Ceprop 4
g/mL, Cpprop was increased stepwise by 1 g/mL
until LOC, allowing plasma effect-site equilibration
between every step, which could be read out in
RUGLOOP II (Demed, Temse, Belgium). Colonos-
copy was then started. Propofol administration was
adjusted to a level of deep sedation in which patients
were no longer responsive to verbal commands and
had no purposeful movements or verbal expressions
of discomfort, while maintaining spontaneous venti-
lation without assistance. The target Cpprop was in-
creased by 0.5 g/mL every minute, if necessary, to
meet this goal. If the patient was unresponsive for 3
min, the target Cpprop was decreased by 0.5 g/mL.
Propofol and remifentanil were administered via a
computer-assisted continuous infusion device (RUGLOOP
II) to a target plasma concentration using a three-
compartment model enlarged with an effect-site com-
partment. For propofol and remifentanil, the
pharmacokinetic-dynamic model previously pub-
lished by Schnider et al.8,9 and Minto et al.10,11 were
used, respectively. Calculated Ceprop was computed
to yield a time-to-peak effect12 of 1.6 min after bolus
injection, as also published by Schnider et al.8,9 and
used clinically by Struys et al.13 For remifentanil, an
equilibration time constant (ke0) of 0.595–0.007 (age
40) was applied as published by Minto et al.10,11
Propofol and remifentanil infusion were administered
using a Fresenius Modular DPS Infusion Pump con-
nected to a Fresenius Base A (Fresenius Vial Infusion
Systems, Bre´zins, France). RUGLOOP II steers the
pump at infusion rates between 0 and 1200 mL/h via
an RS-232 interface. RUGLOOP II was also used to
record the Bispectral Index (BIS) signal (BIS XP Moni-
tor A 2000, Aspect Medical Systems, Newton, MA)
and noninvasive arterial blood pressure, heart rate
(HR), end tidal carbon dioxide (EtCO2), respiratory
rate (RR), and oxygen saturation (SaO2) (AS3 monitor,
Datex, Helsinki, Finland). HR, EtCO2, RR, SaO2, and
BIS were acquired every 10 s. BIS (version 4.0) was
derived from the frontal electroencephalogram (At-
Fpzt) using a BIS XP-Sensor (Aspect Medical Sys-
tems, Newton, MA). Artifacts in the BIS caused by
poor signal quality were automatically detected and
excluded from further analysis. Arterial blood pres-
sure was acquired every 3 min. All data were stored
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on hard disk. Supplemental oxygen (5 L/min) was
supplied by facemask, modified to permit monitoring
of EtCO2, RR, and respiratory pattern.
If no polyps were noticed on insertion of the scope,
administration of both propofol and study drug were
discontinued after the cecum was reached. If polyps
were noted, propofol and study drug were discontin-
ued after polypectomy. Duration of deep sedation was
calculated as the time from the start of the study
product administration to discontinuation of adminis-
tration. Duration of colonoscopy was calculated from
scope in to scope out.
The occurrences of any unwanted effects, such as
movement, inadequate respiration, cardiovascular
side effects and any adverse events or experiences,
were noted. Any intervention to restore normal physi-
ology or respiration was noted.
Immediate recovery was assessed using the Stew-
ard Post Recovery Score (SPRS).14 The times at which
the patients spontaneously opened their eyes, were
able to follow the command to squeeze the investiga-
tor’s hand and were able to state their date of birth
were recorded.
Post hoc all respiratory data were visually inspected.
Artifacts in EtCO2 monitoring and RR caused by poor
signal quality were excluded from further analysis.
Statistical Analysis and Data Presentation
Statistical power was estimated using a blinded
intermittent analysis based on groups of 20 patients
with apnea as the primary end-point. The applied test
was a 2 test. If significant among the groups, the
study was stopped. If not significant, a prospective
power would be calculated.
All values are expressed as means  sd. All data-
sets were tested for Gaussian distribution by a
Kolmogorov-Smirnov test. Between-group analysis
was done using a one-way analysis of variance. If
significant, post hoc testing was done (Bonferroni cor-
rection). Possible changes in within-group observation
were tested using a repeated measures analysis of
variance test. Between-group observations were an-
alyzed using an independent sample t-test with
Bonferroni correction for multiple comparisons.
Continuous data were time-synchronized and com-
pared every 10 s. Categorical data were analyzed
using a Fisher’s exact test. Kaplan-Meier survival
statistics were applied on the time required to reach
a maximum SPRS score.
RESULTS
Patients’ demographics and clinical data were simi-
lar among groups (Tables 1 and 2). Three patients
were excluded from further analysis due to protocol
violation (one from the MCI R group, two from the
TCI R group).
Similar times to LOC (Table 2), Ceprop at LOC
(4.79  1.31 g/mL, 4.41  0.63 g/mL, and 4.59 
0.80 g/mL for MCI R group, TCI R group and
placebo group respectively), and BIS at LOC (Table 2)
were observed in all groups.
Figure 1 shows the individual BIS and predicted
Cpprop and Ceprop in the three groups. Similar over-
all BIS levels were found among groups. Cpprop and
Ceprop were significantly different between the TCI R
and the placebo group from around 10 min after
starting the study and lasting until the end of the
procedure. There were no significant differences in
Ceprop and Cpprop between the MCI R group and the
two other groups.
Figure 2 shows the individual calculated plasma
(Cpremi) and effect-site concentrations of remifentanil
(Ceremi). Although the bolus dose of remifentanil was
given over 2 min in the MCI group, a clear overshoot
in Cpremi was noted. Large interpatient variability can
be observed in the MCI R group for both Ceremi and
Cpremi.
Table 1. Demographic Data
MCI R
group
TCI R
group
Placebo
group
Number (n) 18 18 21
Sex (male/female) 8/10 6/12 5/16
Age (yr)a 39.4 12.5 41.0 13.6 39.9 10.7
Height (cm)a 169.8 9.1 169.1 11.2 167.4 7.1
Weight (kg)a 68.7 12.1 66.4 14.5 73.7 14.5
ASA physical
status (I/II)
15/3 17/1 15/6
Indication (D/C/
P/UC)
13/2/3/0 15/1/2/0 13/3/3/2
MCI  manually controlled infusion; TCI  target-controlled infusion; D  diagnostic; C 
Crohn’s disease; P  polypectomy; UC  ulcerative colitis.
a Age, height and weight are presented as mean  SD, other data are shown as number of
patients.
Table 2. Clinical Data
MCI R group TCI R group Placebo group
LOC (s) 568 147 529 96 570 108
Start colonoscopy (s) 674 219 548 124 667 301
Duration of colonoscopy (s) 859 298 997 465 811 446
Duration of deep sedation (s) 1323 250 1413 495 1309 495
Total dose of propofol (mg) 318 94 289 81* 381 162
Total dose of remifentanil (g) 40 8 36 9 —
BIS at LOC 65 16 69 15 61  15
Data are presented as mean  SD.
MCI  manually controlled infusion; LOC  loss of consciousness; TCI  target-controlled infusion; BIS  bispectral index.
* P  0.056 TCI R group versus placebo group.
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There was no difference in systolic and diastolic
blood pressure and in SaO2 among groups. HR was
significantly more rapid in the placebo group com-
pared to the TCI R group starting at approximately 10
min after the study drug was initiated and lasting
throughout the procedure.
Untoward events are shown in Table 3. Signifi-
cantly more patients in the placebo group showed
movement, cough and hiccup, which transiently inter-
fered with the examination. More respiratory side
effects were found in both remifentanil groups. Apnea
was significantly more frequent in the MCI R group
compared to the TCI R group. Respiratory side effects
were managed by chin lift/jaw thrust in all cases of
obstructive respiration, and with gentle assisted mask
and bag ventilation to prevent desaturation until
Figure 1. Individual bispectral index (BIS) and predicted plasma and effect-site concentrations of propofol. MCI  manual
infusion group; TCI  target-controlled infusion group; PLAC  placebo group. a  P  0.05 between MCI and PLAC and
b  P  0.05 between TCI and PLAC.
Figure 2. Individual predicted plasma
and effect-site concentrations of
remifentanil. MCI  manual infusion
group; TCI  target-controlled infu-
sion group.
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spontaneous ventilation returned in all cases of apnea.
Time of onset of apnea was 414 s and 889 s for the 2
patients in the TCI R group, and ranged from 373 s to
1333 s in the 8 patients of the MCI R group.
Ceprop at recovery of consciousness and recovery
times were comparable among the three groups (Table
4). Survival statistics showed that the time to reach a
maximum SPRS did not differ among groups.
Post hoc analysis of the pharmacokinetic data re-
vealed significant differences among the groups. Time
to reach Ceremi of 0.95 ng/mL (95% of the target
concentration) was 162.65 33.93 s in theMCI R group
versus 325.78  56.41 s in the TCI R group (P  0.05).
Maximum Cpremi (Cpremimax) and Ceremi (Ceremimax)
were significantly higher in the MCI R compared to the
TCI R group. MaximumCeprop (Cepropmax) was signifi-
cantly lower in the TCI R group compared to the placebo
group (Table 5).
When subdividing the MCI R group into patients
who experienced apnea (n  8) versus patients who
did not (n  10), we found a significantly higher
Cpremimax in the apnea group (1.797  0.324 ng/mL
vs 1.490  0.193 ng/mL in the no apnea group).
Ceremimax had a tendency to be higher in the apnea
group (P  0.07). Cepropmax was not significantly
different (4.70  1.24 g/mL vs 5.16  1.20 g/mL in
respectively the apnea and the no apnea group).
DISCUSSION
This study was conducted to investigate two ques-
tions: first, if the advantages of the addition of
remifentanil to propofol in spontaneously breathing
patients surpasses the disadvantages of the combina-
tion of these two products, and second, if administra-
tion of remifentanil via TCI optimizes drug delivery,
resulting in a safer and more reliable technique for
coadministration of propofol and remifentanil.
We found that the addition of remifentanil to
propofol resulted in less movement, hiccup and cough
and thus the combination of remifentanil and propofol
offered better conditions for colonoscopy than propo-
fol used as a single drug. We also found that admin-
istering remifentanil via TCI offered further benefit
compared to manual administration of remifentanil,
as remifentanil TCI reduced propofol requirements
and decreased the incidence of respiratory depression.
Previous studies showed that a single drug is
unable to manage amnesia, analgesia, and immobility
during procedural deep sedation.15 This was con-
firmed in our study, in which movement, cough and
hiccup in the group receiving only propofol frequently
interfered with the examination, making the condi-
tions for colonoscopy less beneficial. This proves the
difficulty of managing noxious stimuli when only
using propofol. We hypothesized that the combined
use of propofol-remifentanil might result in optimal
control of all components of the anesthetic state dur-
ing procedural deep sedation. When coadministering
remifentanil to propofol, we found a decreased inci-
dence of somatic responses. Unfortunately, remifen-
tanil is a potent ventilatory depressant. Nieuwenhuijs
et al.5 studied the remifentanil-propofol interaction on
cardiorespiratory control using the technique of re-
sponse surface modeling. They observed strikingly
synergistic respiratory depression when remifentanil
and propofol are combined, even in low concentra-
tions. When observing the ventilation-CO2 response
curve, the combined administration of remifentanil
Table 3. Events
MCI R
group
(n  18)
TCI R
group
(n  18)
Placebo
(n  21) P*
Purposeful movement 2 5 10 0.044
Nonpurposeful
movement
1 4 4 0.342
Excitatory movement 0 0 3 0.066
Obstructive
respiration
9 10 2 0.008
Bradypnea (RR 6
breaths/min)
8 5 0 0.009
Apnea 8 2 0 0.003
Cough 0 0 4 0.025
Hiccup 0 0 3 0.066
Drowsiness 5 2 3 0.373
Nausea/vomiting 0 0 0 1.000
Data are shown as number of patients.
MCI  manually controlled infusion; TCI  target-controlled infusion; RR  respiratory rate.
* P-value between the three groups obtained with a 2 test as “group * event.”
Table 4. Recovery Data
MCI R
group
TCI R
group
Placebo
group
Ceprop at ROC
(g/mL)
1.80 0.88 1.69 0.48 2.13 0.56
Time to open eyes (s) 350 168 240 116 302 138
Time to follow
command (s)
345 152 260 126 300 117
Time to state date of
birth (s)
348 151 262 125 304 120
Data are presented as mean  SD.
MCI  manually controlled infusion; TCI  target-controlled infusion; ROC  recovery of
consciousness; Ceprop  effect-site concentration of propofol.
Table 5. Maximum Predicted Plasma and Effect-Site
Concentrations
MCI R
group
TCI R
group
Placebo
group
Cpremimax
(ng/mL)
1.627 0.296 1.047 0.110* —
Ceremimax
(ng/mL)
1.223 0.160 0.999 0.001* —
Cepropmax
(g/mL)
4.957 1.208 4.520 0.666† 5.218 0.706
Data are presented as mean  SD.
MCI  manually controlled infusion; TCI  target-controlled infusion; Ceremimax  maximum
effect-site concentrations of remifentanil; Cpremimax  maximum plasma concentrations of
remifentanil; Cepropmax  maximum effect-site concentration of propofol.
* P  0.05.
† P  0.05 TCI R group versus placebo group.
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and propofol yielded both a rightward shift of the
response curve (typical -opioid effect) and a reduc-
tion in the slope of the curve (typical effect of a
hypnotic/sedative). We hypothesized that administra-
tion of remifentanil via TCI would optimize drug
delivery, resulting in a lower incidence of respiratory
side effects.
TCI has been developed to optimize drug delivery
by targeting a specific therapeutic drug concentration
in a specific body compartment. The drug’s typical
pharmacokinetic behavior was first characterized
from clinical pharmacology studies in widely different
patient populations and implemented physiologic or
disease state covariates. All these data are prepro-
grammed into the multi-compartmental pharmacoki-
netic model of the TCI system, minutely describing the
distribution and elimination of the drug within the
body. The TCI system calculates the infusion rate to
achieve and maintain the defined target concentration
as fast and accurately as possible without overshoot.
Because the drug accumulates in the body, the system
frequently recalculates the appropriate drug dosage
and updates the infusion rate, enabling a steady-state
concentration of drug. In other words, TCI systems
reduce both time-dependent variability (by continu-
ously updating the infusion rate) and interpatient
variability (by implementing the effect of covariates
on pharmacokinetics). TCI systems use complex math-
ematical models to compute the drug dosage. It is
impossible to perform these complex calculations and
control drug administration with the same accuracy
when using MCI systems.6
There are no studies demonstrating a clear patient
benefit when using remifentanil through TCI instead
of manually controlled remifentanil administration.
Obviously, to evaluate this, we needed comparable
remifentanil concentrations in the two study groups.
Therefore, we first performed pharmacokinetic simu-
lations, using the RUGLOOP II program, to ensure
similar calculated remifentanil effect-site concentra-
tions, as well as a similar concentration trajectory in
the two remifentanil groups. A bolus dose of 0.25
g/kg given over 2 min, followed by a continuous
infusion of 0.05 g  kg1  min1 gave the best ap-
proximation of the target Ceremi of 1 ng/mL. As
shown in Figure 2, the simulation was very accurate
since the mean Ceremi approached 1 ng/mL in the
MCI R group.
Despite our efforts to imitate the TCI profile as
closely as possible, overshoot, interpatient variability,
and accumulation of remifentanil was noted in the
MCI group. This is clearly depicted in Figure 2. Post
hoc analysis of our pharmacokinetic data also revealed
that Cpremimax and Ceremimax were significantly
higher in the MCI R group compared to the TCI R
group.
We realize that concentrations reported by the TCI
system are predicted, not true concentrations, and there-
fore the difference between the MCI R and the TCI R
group is a function of the pharmacokinetic-dynamic
model used. We did not measure remifentanil plasma
concentrations, since the pharmacokinetic-dynamic
model we used has been demonstrated as adequately
accurate in predicting plasma and effect-site concentra-
tions of remifentanil.10,11 However, higher variability,
overshoot and accumulation of drug in the MCI group
compared to the TCI group is well known and was not
surprising, since, as mentioned before, TCI evaluates the
complexity of the drug pharmacokinetic characteristics,
which manual administration regimen cannot.6
In our study, it is remarkable that, although we
designed our MCI group to receive virtually the same
effect-site concentration as our TCI group, we found
significant differences. We found a significantly higher
incidence of apnea of the MCI R group compared to the
TCI R group (Table 3). We also found that remifentanil
administered via TCI resulted in a decrease in propofol
requirements (Table 5, Fig. 1).
It is possible that the difference in incidence of
apnea is solely attributable to a dosing difference.
When comparing patients who experienced apnea
versus patients who did not, Cpremimax was signifi-
cantly higher in the apnea group. If the difference in
incidence of apnea was indeed due to the dosing
difference, this means that the pharmacokinetic inaccu-
racy, which is inherent to manual controlled infusions,
has important pharmacodynamic repercussions. This is
especially important in situations in which there is little
room for error, as is the case with remifentanil in
spontaneously breathing patients.
Another explanation for the difference in apnea
between the MCI R and the TCI R group could be the
more bolus type of administration of remifentanil at
the beginning of the administration in the MCI R
group. In the MCI R group, Ceremi of 0.95 ng/mL was
reached twice as fast as in the TCI R group. One would
suppose that, if the difference was due to this more
rapid bolus administration in the MCI R group, the
major difference between the groups would have been
at induction. However we found no difference in time
of onset of apnea between the two groups. One reason
could be, as stated by Bouillon et al.,16 that RR is not a
good indicator for respiratory depression. They state
that an increase in tidal volume variability is a better
predictor of respiratory depression than decreased
RR. Since this was a study performed in a clinical
situation the tools to measure tidal volume variability
were not available.
Besides the difference in incidence in apnea, we also
found a difference in propofol concentrations among the
study groups. Cpprop, Ceprop, and Cepropmax were
significantly lower in the TCI R group compared to the
placebo group, whereas the propofol concentrations in
the MCI group did not differ from the two other groups.
According to the study protocol, the target Cpprop was
decreased by 0.5 g/mL if the patient was unre-
sponsive for 3 min. In Figure 1, we depicted the
Cpprop of all patients individually. From this figure,
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it is clear that in the TCI group the decrease of the
propofol target concentration is consistent, whereas
in the MCI group decreasing the propofol target
concentration was more burdensome. We presume
that this was due to the large interindividual vari-
ability in remifentanil concentrations in the MCI
group making deep sedation far less manageable.
In conclusion, we have shown that the addition of
remifentanil to propofol provides more stable anes-
thetic conditions compared with propofol used as a
single drug. Administering remifentanil via TCI dur-
ing spontaneous ventilation results in a decrease in
propofol dosing and in a lower incidence in apnea
compared to remifentanil administered via MCI.
Since the combination of propofol and remifen-
tanil, even in TCI, still results in strikingly synergis-
tic respiratory depression, careful monitoring of
respiratory function and appropriate skills in the
recognition and treatment of inadequate respiration
remain mandatory.
REFERENCES
1. Moerman A, Struys MMRF, Vereecke H, Herregods L, De Vos
M, Mortier E. Remifentanil used to supplement propofol does
not improve quality of sedation during spontaneous respiration.
J Clin Anesth 2004;16:237–43
2. Murdoch JA, Hyde RA, Kenny GN. Target-controlled remifen-
tanil in combination with propofol for spontaneously breathing
day-case patients. Anaesthesia 1999;54:1028–31
3. Peacock JE, Luntley JB, O’Connor B, et al. Remifentanil in
combination with propofol for spontaneous ventilation anaes-
thesia. Br J Anaesth 1998;80:509–11
4. Joo HS, Perks WJ, Kataoka MT, Errett L, Pace K, Honey RJ. A
comparison of patient-controlled sedation using either remifen-
tanil or remifentanil-propofol for shock wave lithotripsy.
Anesth Analg 2001;93:1227–32
5. Nieuwenhuijs D, Olofsen E, Romberg R, Sarton E, Ward D,
Englbers F, Vuyk J, Mooren R, Teppema L, Dahan A. Response
surface modeling of remifentanil-propofol interaction on cardio-
respiratory control and bispectral index. Anesthesiology
2003;98:312–22
6. Egan TD. Target-controlled drug delivery. Anesthesiology
2003;99:1214–19
7. Babenco HD, Conard PF, Gross JB. The pharmacodynamic effect
of a remifentanil bolus on ventilatory control. Anesthesiology
2000;92:393–8
8. Schnider TW, Minto CF, Shafer SL, Gambus PL, Andresen C,
Goodale DB, Youngs EJ. The influence of age on propofol
pharmacodynamics. Anesthesiology 1999;90:1502–16
9. Schnider TW, Minto CF, Gambus PL, Andresen C, Goodale DB,
Shafer SL, Youngs EJ. The influence of method of administration
and covariates on the pharmacokinetics of propofol in adult
volunteers. Anesthesiology 1998;88:1170–82
10. Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJ,
Gambus PL, Billard V, Hoke JF, Moore KH, Hermann DJ, Muir
KT, Mandema JW, Shafer SL. Influence of age and gender on the
pharmacokinetics and pharmacodynamics of remifentanil: I.
Model development. Anesthesiology 1997;86:10–23
11. Minto CF, Schnider TW, Shafer SL. Pharmacokinetics and
pharmacodynamics of remifentanil: II. Model application. An-
esthesiology 1997;86:24–33
12. Shafer SL, Gregg KM. Algorithms to rapidly achieve and
maintain stable drug concentrations at the site of drug effect
with a computer-controlled infusion pump. J Pharmacokinet
Biopharm 1992;20:147–69
13. StruysMM, De Smet T, Depoorter B, Versichelen LF, Dumortier FJ,
Shafer SL, Rolly G. Comparison of plasma compartment versus
two methods for effect compartment-controlled target-controlled
infusion for propofol. Anesthesiology 2000;92:399–406
14. Steward DJ. A simplified scoring system for the postoperative
recovery room. Can Anaesth Soc J 1975;22:111–13
15. Moerman A, Foubert L, Herregods L, Struys MM, De Wolf D,
De Looze D, De Vos M, Mortier E. Propofol versus remifentanil
for monitored anaesthesia care during colonoscopy. Eur J An-
aesthesiol 2003;20:461–6
16. Bouillon T, Bruhn J, Roepcke H, Hoeft A. Opioid-induced
respiratory depression is associated with increased tidal volume
variability. Eur J Anaesthesiol 2003;20:127–33
834 Manual Versus TCI Remifentanil ANESTHESIA & ANALGESIA
